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ABSTRACT
Introduction: Surgical resection of a malignant
bone tumor (BT) or soft tissue tumor (STT), with
or without prosthetic replacement, carries a
high risk of developing postoperative
infections. There is limited knowledge on the
bacteriological spectrum of these postsurgical
infections that necessitate empirical antibiotic
therapy. The aim of this study was to analyze
the incidence and microbiological features of
site infections following BT or STT resection.
Methods: In this retrospective mono-center
study, we analyzed the surgical and
bacteriological data of all consecutive patients
who developed an infection after surgical
resection of a BT or STT between January 2010
and April 2014.
Results: Seventy-two consecutive patients who
developed an infection on the site of surgical
treatment for a BT (n = 42) or SST (n = 30) were
included. Polymicrobism was frequently
observed, more often associated with STTs
(93%) than BTs (71%; P = 0.03).
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Gram-negative bacteria were more frequently
isolated in STTs (55%) than in BTs (26%;
P = 0.01) and non-prosthesis-associated
infections (54%) than prosthesis-associated
infections (29%; P = 0.04), whereas
staphylococci were more frequently found in
BTs (76%) than in STTs (52%; P = 0.03). Overall,
we found gram negatives in 82% of early acute
infections, 11% of chronic infections and 7% of
late acute infections (P\0.01).
Conclusion: Postoperative infections in patients
after surgical resection of BTs or STTs were often
polymicrobial, especially following STTs.
Causative bacteria were often gram negatives in
STTs and non-prosthesis-associated infections,
whereas staphylococci were predominant in BTs.
Based on these findings, we recommend
antibiotic coverage of both gram-positive and
-negative bacteria with a combination of
broad-spectrum antibiotics in STTs and
antistaphylococcal antibiotics as first-line
therapy in infections following BT surgery.
Keywords: Bone tumor; Infection postsurgical
resection; Microbiology; Soft tissue tumor
INTRODUCTION
Patients undergoing surgical resection for a
malignant bone tumor (BT) or soft tissue tumor
(STT), e.g., sarcomas, are at high risk for infectious
complications [1]. A recent meta-analysis of 48
studies involving 4838 patients who underwent
surgery for malignant BTs of the lower extremities
showed a postoperative infection rate of 10% [2].
Similar postoperative infection rates of around
10% were reported in STT patients [3]. A longer
duration of surgery, invalidating surgery, impaired
systemic or local immunosuppressive state due to
chemotherapy or adjuvant radiation, poor general
performance status and implanted material left at
the operative site may decrease host defenses,
leading to infection [4, 5]. Postsurgical infections
can lead to reoperation with frequent need for
prosthesis removal [6] in combination with
antibiotic treatment, decreased function of the
extremity and increased pain resulting in
incremental healthcare costs [3, 7, 8].
In the absence of renewed surgical
intervention, antibiotic therapy for
postsurgical infections shows success rates
lower than 10% [1]. One of the reasons for
this low success rate is the lack of data
concerning the microbiological spectrum of
infections following surgery for BTs and STTs.
First, isolation and identification of all causing
bacteria are time consuming and not always
successful [6]. Furthermore, there are hardly any
large studies performed in patients with
postsurgical infections after resection of a BT
or STT. This results in limited data to guide
first-line antibiotic therapy. The optimal way,
e.g., the gold standard, to establish the
microbiological spectrum of a postoperative
infection is to obtain peroperative cultures
from the surgical site of a postsurgical
infection. Postsurgical infections following
resections of BTs and STTs are associated with
high patient morbidity, and therefore precise
microbiological data are needed for better
empiric antibiotic therapy.
This study aimed at evaluating the
bacteriological spectrum of malignant BT- and
STT-associated postsurgical infections in order
to improve the effectiveness of antibiotic
treatment, thereby decreasing patient
morbidity. We show that different causative
agents observed for either BT or STT
postsurgical infections are involved and that
this knowledge could help clinicians to
redefine more specific empirical antibiotic
treatments in both cases.
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METHODS
Study Design
We performed a retrospective observational
monocenter study of all consecutive adult
patients who had a surgical resection in the
orthopedic department of a malignant primary
or secondary BT, or a malignant STT, presenting
with a postsurgical infection between 1 May
2010 and 1 April 2014 at the Cochin Hospital
(Paris Descartes University, Paris, France).
Cochin Hospital is a tertiary referral center for
BTs and STTs with a separate infectious diseases
ward within the orthopedic department. The
treatment of all patients is discussed weekly in a
multidisciplinary infection meeting (MDIM)
attended by orthopedic surgeons,
anesthesiologists, medical microbiologists,
infectious disease physicians and pharmacists.
All procedures followed were in accordance
with the ethical standards.
Inclusion Criteria
Inclusion criteria were (1) histologically
confirmed diagnosis of a malignant primary or
secondary BT or a malignant STT, (2) surgical
treatment for the tumor (tumor resection
whether or not followed by reconstruction),
(3) age above 15 years at the time of infection
and (4) at least one postsurgical infection at the
resection site confirmed by the treating staff.
Since only cultures of peroperative samples
were considered as relevant for microbiological
documentation, patients were excluded if they
did not get surgical treatment for their
infection. Patients who underwent surgery
more than once during infection treatment
were included only once. Visceral
mesenchymal tumors were excluded.
Data Collection
The following data were collected from the
medical records: (1) age, (2) sex, (3) body mass
index (BMI, kg/m2), (4) American Society of
Anesthesiologists (ASA) score at the time of
infection, (5) tumor histology, (6) details of
surgical and nonsurgical treatments (e.g.,
chemotherapy and radiotherapy) for the
tumor, (7) bacteriological documentation
before and at the time of surgical
interventions for all (re)infection(s), and (8)
surgical and antibiotic treatment of the
(re)infection(s). For most patients, data on
peroperative antibiotic prophylaxis were not
properly documented and were therefore not
collected.
Histological data confirming the diagnosis of
malignant tumor, including the type of tumor,
localization and grade, were retrieved from
either pre- or peroperative histological
material, anesthesiological files or external
documentation. Bacteriological data, e.g.,
bacteria and antibiotic resistance patterns,
were collected from pre-, per- or postoperative
biological samples, blood or any suspected port
of entry. Medical treatment data were collected
for both tumors and infections. For tumors, the
types of surgical intervention and treatments
with pre- or postoperative chemo- or
radiotherapy were retrieved from all surgical
operation reports. For the (re)infections, the
type of surgical intervention was noted.
Postoperative antibiotic treatment for
infection was evaluated for theoretical
effectiveness using the antibiotic susceptibility
testing pattern of the bacterial isolates that were
considered as causative pathogens, e.g., isolated
from pre- or peroperative specimens. The
mono- or polymicrobism was analyzed, as well
as the incidence of different pathogens gathered
in different categories.
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Methods for Bacteriological Isolation
and Antibiotic Susceptibility Testing
Peroperative samples were homogenized before
streaking onto two sets of horse blood and
heated blood agar (BioMerieux, France) and
incubated under aerobic or anaerobic
conditions at 35 C. One agar set was observed
up to 48-h incubation, and the second set was
left untouched until examination at day 7.
A Schaedler enrichment broth (BioMerieux,
France) was also inoculated and examined
daily up to 14 days. Bacterial isolates of
interest were identified using MALDI TOF
(MALDI BioTypr, BrukerDaltonik, Germany),
and antibiotic susceptibility testing was
conducted by disc diffusion method in
accordance with EUCAST 2013 guidelines.
When available, rectal carriage of
extended-spectrum beta-lactamase (ESBL) and
nasal carriage of methicillin-resistant
Staphylococcus aureus (MRSA) at the time of
infection were retrieved from the
bacteriological files.
Definitions
Tumors were subdivided into malignant
primary and secondary BTs or malignant STTs.
Oncologic surgical treatments were subdivided
based on type of surgery: tumor resection or
limb amputation (e.g., non-prosthetic) or tumor
resection with prosthesis implantation,
including osteosynthesis and/or allograft
implantation. Localization was subdivided into
(1) the upper limb from the shoulder joint to
hand, (2) ribs and/or spine, (3) pelvis, including
the sacrum and tumors in both the pelvis and
hip, and (4) lower limb from the hip joint to
foot, including tumors in both the leg and hip.
The oncologic grade of the tumors was
subdivided into 1, 2 or 3 (French FNCLCC
grading system) for STTs and a low or high
grade (Enneking grading system) for BTs.
The diagnosis of infection was derived from
consensus by the MDIM, based on the clinical
presentation and inflammatory signs (e.g.,
general signs such as fever, malaise and local
symptoms such as pain, redness, swelling,
hardness and fluid leakage from surgical scars),
operation reports and laboratory findings
[blood C-reactive protein (CRP), abundance of
leukocytes in peroperative samples). A
distinction was made between osteomyelitis
(bone infection) and erysipelas/cellulitis (soft
tissue infection) at the time of the MDIM based
on surgical, radiological and clinical evidence
for osteitis. Infection was categorized as early
acute (\1 month postresection), late acute
(1–3 months postoperative) or chronic
([3 months postoperative).
All infections were first treated surgically,
and antibiotic treatment was started
peroperatively as soon as clinical samples had
been obtained, with a recommended duration
of 6–12 weeks (osteomyelitis) or 21 days
(cellulitis). Surgical treatments for infection
were subdivided according to surgery type.
Antibiotic therapy given for postoperative
surgical site infections was subdivided in (1)
monotherapy for each bacterial isolate, (2)
combination therapy for all isolated bacteria,
(3) the antibiotic spectrum not covering all
infectious bacteria, (4) probabilistic antibiotic
therapy with negative microbiological cultures
or (5) no antibiotic therapy.
Statistical Analysis
We performed a descriptive analysis of clinical
and bacteriological data. The primary endpoint
of this study was the difference in causative
bacteriological pathogens of postsurgical
infections between BTs and STTs. Secondary
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endpoints were differences in causative
bacteriological pathogens among (1) three
different types of infection (osteomyelitis,
cellulitis or both), (2) four different
localizations (upper limbs, vertebrae, pelvis or
lower limbs) and (3) prosthesis or
non-prosthesis-associated infections combined
with nonsurgical tumor treatments, e.g.,
chemo- or radiotherapy pre- or
postoperatively. Continuous variables were
expressed as medians with interquartile range
(IQR; Q1–Q3), whereas categorical variables
were noted as numbers with percentages (%).
We used the t test or one-way analysis of
variance test for continuous variables with a
normal distribution and a v2 test or Fisher exact
test (*) for categorical variables. A two-sided
P value of \0.05 was considered statistically
significant. Person-years of follow-up for each
patient were computed as the time from the
index date (date of first presentation with
infection at the hospital) to the end of
follow-up (1 April 2014), death or loss to
follow-up. Statistical analysis was performed




Seventy-two consecutive patients who
developed a postsurgical infection after
resection of a BT (n = 42) or STT (n = 30) were
included (Fig. 1). The study population is
detailed in Table 1 and consisted of 34 males
and 38 females with a mean age of 49.8 years
(SD ± 19.2) and a mean BMI of 25.7 kg/m2
(SD ± 5.1).
Fig. 1 Flowchart inclusion of the 72 patients who had a postoperative site infection after surgery for a BT or STT
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Table 1 Baseline characteristics of 72 patients with an infection following surgical treatment of a BT or STT
Characteristics All patients (N5 72) BT (N5 42) STT (N5 30) P value
Sex, male 34 (47.2) 24 (57.1) 10 (33.3) 0.046
Age at time of infection, years (mean ± SD) 49.8 ± 19.2 44.6 ± 17.4 57.1 ± 19.5 0.006







ASA C3 22 (30.6) 12 (28.6) 10 (33.3) 0.665















Upper limb 4 (5.6) 3 (7.1) 1 (3.3) 0.636*
Vertebrae or ribs 4 (5.6) 4 (9.5) 0 0.135*
Pelvisa 13 (18.1) 9 (21.4) 4 (13.3) 0.379
Lower limbb 51 (70.8) 26 (61.9) 25 (83.3) 0.049
High gradec of primary tumor 28 (66.7) 9 (52.9) 19 (76) 0.120
Nonsurgical treatment for tumor
Chemotherapy 29 (40.3) 19 (45.2) 10 (33.3) 0.310
Radiotherapy 21 (29.2) 5 (11.9) 16 (53.3) 0.000
Type of infection
Bone infectiond 37 (51.4) 31 (73.8) 6 (20) 0.000
Soft tissue infectiond 31 (43.1) 8 (19) 23 (76.7) 0.000
Bone and soft tissue infectiond 4 (5.6) 3 (7.1) 1 (3.3) 0.636*
Last tumor operation—infection, days (mean ± SD) 186 ± 787 278 ± 1023 56 ± 88 0.240
Onset and duration of symptoms 0.811
Early acute infectione 40 (55.6) 22 (52.4) 18 (60)
Late acute infectione 19 (26.4) 12 (28.6) 7 (23.3)
Chronic infectione 13 (18.1) 8 (19) 5 (16.7)
Infection management
Surgery for (re)infection(s), n (mean ± SD) 1.8 ± 1.1 1.9 ± 1.1 1.7 ± 1.0 0.420
[1 surgical operation for infection 36 (50) 22 (52.4) 14 (46.7) 0.633
AB after ﬁrst surgery for infection 68 (94.4) 40 (95.2) 28 (93.3) 1.000*
AB monotherapy for C1 causative agent 27 (39.7) 8 (20) 19 (67.9) 0.000
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Histological Features and Treatments
for Tumor
BTs (n = 42) consisted of primary BTs (79%)
and secondary BTs (21%). Histological and
oncological characteristics of the tumors are
presented in Table 1. Surgical treatment
involved tumor resection with limb salvage in
96% and amputation in 4% (BTs 0%, STTs
10%; P = 0.07). Reconstruction involved a
prosthesis in 36% (BTs 57%, STTs 7%;
P\0.01) and allograft and/or osteosynthesis
in 26% (BTs 29%, STTs 23%; P = 0.60).
Chemotherapy following tumor resection was
more frequent in the upper limb (BTs 50%,
STTs 0%) and vertebral tumors (BTs 50%, STTs
0%) than in pelvic (0%) and lower limb tumors
(BTs 23%, STTs 20%; P = 0.03). Preoperative
radiotherapy was performed significantly more
often in patients with subsequent cellulitis
(39%) than in those with osteomyelitis (16%;
P = 0.04).
Clinical Characteristics of the Infections
Infection characteristics are shown in Table 1.
The median duration between the last
oncological operation and first infectious
episode was 28 days (IQR 13–72 days). Infections
were considered as early acute (\1 month) in 40
patients (56%), late acute (1–3 months) in 19
(26%) and chronic ([3 months) in 13 (18%).
Thirty-seven (51%) patients were diagnosed with
osteomyelitis (31 BT patients, 6 STT patients), 31
(43%) with cellulitis (8 BT patients, 23 STT
patients) and 4 (5%) with both (3 BT patients, 1
STT patient; Fig. 1). In 68 patients (94%), the
causative pathogen was obtained by culture,
whereas no causative pathogen was identified in
the remaining four patients, despite clinical and
histological evidence for infection at revision
surgery. Blood cultures were available for 30
patients, of whom 6 (20%) had a bacteremia
with the same pathogen as found at the surgical
site.
Table 1 continued
Characteristics All patients (N5 72) BT (N5 42) STT (N5 30) P value
AB combitherapy against all causative agents 36 (52.9) 28 (70) 8 (28.6) 0.001
AB suppressive therapy 5 (6.9) 4 (9.5) 1 (3.3) 0.393*
Values are presented as n (%) unless otherwise stated
Bold indicates signiﬁcant P values
Histology of tumors: primary BTs included: osteosarcomas (n = 18), chondrosarcomas (n = 5), Ewing tumors (n = 2),
chordomas (n = 3), giant cell tumors (n = 2), adamantinomas (n = 2) and undifferentiated BTs (n = 1). Secondary BTs
(n = 9) were all metastatic adenocarcinoma. STTs (n = 30) included: synovialosarcomas (n = 2), (myxo)ﬁbrosarcomas
(n = 7), leiomyosarcomas (n = 4), liposarcomas (n = 7), rhabdomyosarcomas (n = 1) or undifferentiated STTs (n = 9)
AB antibiotic, ASA American Society of Anesthesiologists, BMI body mass index, BT bone tumor, ESBL extended-spectrum
beta-lactamase, MRSA methicillin-resistant Staphylococcus aureus, STT soft tissue tumor
* Fisher’s exact test. If no *, an v2 test was used
a Including tumors in the hip or pelvis
b Including tumors in the hip or leg
c French FNCLCC grading system (high grade = grade 3) for soft tissue tumors and Enneking grading system (high
grade = grade 2) for bone tumors
d Bone infection = treated with antibiotics for C4 weeks; soft tissue infection = treated with antibiotics for
2 days–3 weeks; both = treated with antibiotics at least once for 6 weeks and at least once for 2 weeks
e Early\1 month, late[1 month after last surgery for tumor
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Table 2 Bacteriological documentation of the 72 infections in patients surgically treated for a BT or STT
Bacteria in ﬁrst intervention All patients (N 5 71) BT (N 5 42) STT (N 5 29) P value
Causing organisms at ﬁrst intervention
Patients with positive culture 68 (95.8) 40 (95.2) 28 (96.6) 1.000*
Patients with gram-positive species 62 (87.3) 37 (88.1) 25 (86.2) 1.000*
Patients with gram-negative species 27 (38) 11 (26.2) 16 (55.2) 0.013
Patients with anaerobic species 15 (21.1) 6 (14.3) 9 (31) 0.089
Polymicrobism 44 (62) 30 (71.4) 27 (93.1) 0.032
Number of species, n (mean ± SD) 2.38 ± 1.57 2.00 ± 1.53 2.93 ± 1.49 0.013
Staphylococci 47 (66.2) 32 (76.2) 15 (51.7) 0.032
MSSA 24 (33.8) 16 (38.1) 8 (27.6) 0.357
MRSA 0 0 0 –
MSCNSa 18 (25.4) 12 (28.6) 6 (20.7) 0.453
MRCNSb 14 (19.7) 11 (26.2) 3 (10.3) 0.099
Streptococci 12 (16.9) 4 (9.5) 8 (27.6) 0.059*
S. pneumoniae 1 (1.4) 0 1 (3.4) 0.408*
S. agalactiae/S. dysgalactiae 5 (7) 2 (4.8) 3 (10.3) 0.393*
Other streptococcic 6 (8.5) 2 (4.8) 4 (13.8) 0.218*
Other gram-positive species 25 (35.2) 8 (19) 17 (58.6) 0.001
Enterococcid 23 (32.4) 8 (19) 15 (51.7) 0.004
Other gram-positivese 3 (4.2) 0 3 (10.3) 0.064*
Gram negatives 27 (38) 11 (26.2) 16 (55.2) 0.013
Non-ESBL Enterobacteriaceaef 25 (35.2) 10 (23.8) 15 (51.7) 0.015
P. aeruginosag 5 (7) 3 (7.1) 2 (6.9) 1.000*
Other gram negativesh 3 (4.2) 1 (2.4) 2 (6.9) 0.563*
Anaerobes 15 (21.1) 6 (14.3) 9 (31) 0.089
P. acnesi 4 (5.6) 4 (9.5) 0 0.140*
Other anaerobic speciesj 11 (15.5) 2 (4.8) 9 (31) 0.005*
Values are presented as n (%) unless otherwise stated
Bold indicates signiﬁcant P values
BT bone tumor, ESBL extended-spectrum beta-lactamase, MRCNS methicillin-resistant coagulase-negative staphylococcus, MRSA
methicillin-resistant S. aureus, MSCNS methicillin-susceptible coagulase-negative staphylococcus, MSSA methicillin-susceptible S. aureus,
P. acnes Proprionibacterium acnes, P. aeruginosa Pseudomonas aeruginosa, S. agalactiae Streptococcus agalactiae, S. dysgalactiae Streptococcus
dysgalactiae, S. pneumoniae Streptococcus pneumonia, STT Soft tissue tumor
* Fisher’s exact test (v2 test was used in other cases)
a Staphylococcus epidermidis, Staphylococcus capitis, Staphylococcus warnerii, Staphylococcus haemolyticus, Staphylococcus caprae, Staphylococcus
pasteuri, Staphylococcus lugdunensis, Staphylococcus hominis
b Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus capitis, Staphylococcus hominis
c Streptococci or related: Streptococcus anginosus, Streptococcus sangnuinis, Streptococcus oralis, Streptococcus constellatus, Streptococcus
salivarius, Granulicatella adiacens, Helcococcus sp., Gemella morbillorum
d Enterococcus faecium, Enterococcus faecalis, Enterococcus durans, Enterococcus rafﬁnosus
e Dermabacter hominis, Corynebacterium spp. (C. jeikeium, C. amycolatum, C. ramosum, C. perfringens, C. simulans, C.
tuberculostearicum), Actinobaculum schaalii
f Escherichia coli, Serratia marcescens, Klebsiella pneumoniae, Enterobacter aerogenes, Enterobacter cloacae, Proteus mirabilis, Morganella
morganii, Cronobacter sakazakii, Leclercia adecarboxylata, Citrobacter amalonaticus
g And Pseudomonas stutzerii (1 patient)
h Acinetobacter baumannii, Stenotrophomonas maltophilia
i And Proprionibacterium avidum
j Bacteriodes fragilis, Bacteriodes ovatus, Finegoldia magna, Prevotella intermedia, Peptoniphilus harei, Actinomyces odontolyticus, A.
turicensis, Parvimonas micra
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Microbiological Features
Microbiological findings associated with
postsurgical infections after resection of BTs
and STTs are presented in Table 2 and Fig. 2.
Forty-four patients (62%) had a polymicrobial
infections. Polymicrobial infection occurred














Bone tumors: bacteria isolated at ﬁrst surgery
(%)
SAMS SCN MS SCN MR
Bèta hemolyc streptococ Other streptococ Enterococ
Non-ESBL enterobacter Pseudomonas Other gram negave














So ssue tumors: bacteria isolated at ﬁrst
surgery (%)
SAMS SCN MS SCN MR
S. pneumoniae Bèta hemolyc streptococ Other streptococ
Enterococ Other gram posives Non-ESBL enterobacter
Pseudomonas Other gram negave Other anaerobics
(a)
(b)
Fig. 2 Incidence of bacteria in pre-, per- and postoperative
samples of the ﬁrst intervention for infection. Groups of
species are shown as percentages of the total number of
bacteria isolated from the ﬁrst surgery (n = 142, 71 in BT
and 71 in STT) in 71 patients from whom samples were
retrievable. Betahaemolytic streptococci = Streptococcus
agalactiae/Streptococcus dysgalactiae. Pseudomonas = P.
aeruginosa and P. stutzeri. ESBL Extended-spectrum
beta-lactamase, SAMS Staphylococcus aureus methicillin-sus-
ceptible, SCN MR Staphylococcus coagulase-negative
methicillin-resistant, SCN MS Staphylococcus coagu-
lase-negative methicillin-susceptible
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71%; P = 0.03) and likewise in cellulitis versus
osteomyelitis patients (77% vs. 51%; P = 0.01;
Fig. 1). Localization was not linked with the
number of causative pathogens, nor was the
timing of infection (i.e., early acute, late acute
or chronic).
Staphylococci as a group were significantly
more predominant in BTs than in STTs (76% vs.
52%; P = 0.03). S. aureus was present in 38% of
BTs and 28% of STTs (P = 0.36) and
coagulase-negative staphylococci (CNS) in 50%
of BTs and 28% of STTs (P = 0.06). Other
gram-positive bacteria were significantly more
frequent in STTs than in BTs (86% vs. 29%;
P\0.01), among which enterococci (52% vs.
19%; P\0.01) and streptococci (28% vs. 10%;
P = 0.06) were predominant. Gram-negative
bacteria were also significantly more frequent
in STTs than in BTs (55% vs. 26%; P = 0.01),
among which non-ESBL Enterobacteriaceae
(24% vs. 52%; P = 0.02) and Pseudomonas
aeruginosa (7% vs. 7%; P = 1.00) were most
frequent.
We compared the microbial spectrum
between prosthesis-associated infections
(including patients’ allografts and
osteosynthesis material) and non-prosthesis-
associated infections. We found that
gram-negative bacteria occurred more
frequently in postoperative infections without
prosthesis material, 54% vs. 29% (P = 0.04).
Enterococci were more frequent in
non-prosthesis-associated infections, 67% vs.
11% (P\0.01). Furthermore, the number of
cultured bacteria was less in
prosthesis-associated infections, with a mean
4.19 ± 2.56 bacteria in non-prosthesis infections
and 2.96 ± 1.83 in prosthesis-associated
infections (P = 0.05). We also subdivided BT
and STT patients and compared their
microbiological spectrum according to tumor
treatment, e.g., resection and/or prosthesis in
combination with additional chemo- or
radiotherapy. In non-prosthesis-associated
infections with or without additional chemo- or
radiotherapy in BT patients, we found more
frequent gram-negative bacteria (67% vs. 19%;
P = 0.03), Enterococci (67% vs. 11%, P\0.01),
Enterobacteriaceae (67% vs. 17%; P = 0.02) and
anaerobes (33% vs. 0%; P = 0.02). For STT
patients no significant differences were found in
the microbiological spectrum when comparing
tumor treatment groups.
When comparing cellulitis and osteomyelitis
infection irrespective of underlying
malignancy, no significant differences were
seen in the distribution of gram positives and
gram negatives. However, anaerobes were more
frequently isolated from cellulitis (30%) than
from osteomyelitis (5.4%; P = 0.03).
Localization did not significantly affect the
scope of causative pathogens, except for
Proprionibacterium acnes, which was more
frequent in the upper limbs compared to the
vertebrae, pelvis and lower limbs (P = 0.02).
For BTs and STTs together, we found gram
negatives in 82% of early acute infections, in
7% of late acute infections and in 11% of
chronic infections (P\0.01).
Treatments for Infection
Surgery was followed by antibiotic treatment for
almost all patients (99%). Thirty-six patients
(50%) had one surgical intervention and 36
(50%) had more than one.
The median duration of antibiotic treatment
was 3.7 weeks (IQR 5 weeks), with a median of
4.4 weeks for BT patients (IQR 4 weeks) and
2.3 weeks for STT patients (IQR 2 weeks;
P = 0.08). Antibiotic therapy duration
C6 weeks was more frequently associated with
successful clinical outcome in BTs (and
osteomyelitis) than a shorter duration
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(\6 weeks) of antibiotic therapy (53% vs. 16%;
P = 0.02). In STTs and cellulitis, no significant
difference in clinical outcome was seen between
a longer (C3 weeks) or shorter (\3 weeks)
duration of antibiotic therapy (57% vs. 29%;
P = 0.36). Five (7%) patients received lifelong
suppressive antibiotics as an alternative to
further surgical treatment, either after the first
surgery (n = 3) or one of the following surgeries
(n = 2).
Antibiotic choice was made by clinicians and
was confirmed through MDIM. Thirty-five
different molecules were used. The most
frequently used antibiotics as initial
monotherapy or combination therapy were
the following: piperacillin-tazobactam (13%),
amoxicillin/clavulanic acid (10%), gentamicin
(9%), pefloxacin (9%) or vancomycin (9%).
Thirty-one percent of initial antibiotherapies
were switched to a second line mono- or
combination antibiotherapy, involving
gentamicin (60%), vancomycin (48%),
amoxicillin/clavulanic acid (25%), pefloxacin
(17%) and tazobactam (15%).
DISCUSSION
We studied the microbiological spectrum of
infections following surgical resection of BTs
and orthopedic STTs in a relatively large
number of patients, presenting the largest
patient group of postoperatively infected STTs
patients (n = 30) to our knowledge.
First, we show that postoperative infections
in STTs are polymicrobial in 88% of the cases,
whereas post-BT infections are more frequently
monomicrobial, involving mainly
staphylococci. Several reasons can be
hypothesized for polymicrobism in BTs and
STTs: high risk of post-resection hematoma
leading to colonization with microbiota
anaerobic bacteria [9], radiotherapy prior to
surgery causing tissue hypo-oxygenation [10]
and resection of tumors located near the pelvis
that can lead to breaches in the digestive tract
[11]. Few microbiological data on STTs are
available in the literature. Only the study of
Morii et al. [6] reported seven cases of STT
patients, four of them presenting with
postoperative infection due to S. aureus (50%
MRSA), two with gram-negative bacteria (n = 2)
and one with polymicrobial infection. In our
study, gram-positive bacteria were predominant
in both BT (88%) and STT infections (86%).
Second, we found that gram-negative
bacteria, e.g., Enterobacteriaceae, were
significantly more frequently isolated in STT
patients than in BT patients (55% vs. 26%).
Differences in patient characteristics such as
surgical treatment, presence or absence of
prostheses, and other potential risk factors
such as age, sex comorbidities [12] and
radiotherapy could explain differences in the
distribution of microbial spectra between BTs
and STTs (and between osteomyelitis and
cellulitis).
Our microbiological data concerning BTs
(n = 42) are congruent with previous studies.
Gram-positive bacteria were isolated in 88% of
the BT patients in our study, as compared to
63% in the study by Angelini et al. [13].
Furthermore, in our study 71% of infections in
BTs were polymicrobial, as compared to 26% [1]
to 38% [10] of BTs and 74% of sacral BTs [14]
reported by others. In prosthesis-associated
nontumoral bone infections, monomicrobial
infections—with a majority of staphylococci
[2]—predominate, whereas in postsurgical BT
infections the microbiological spectrum is often
polymicrobial (38%) with gram-positive and
-negative bacteria [13]. Staphylococci were
predominant in BTs (76% in our study, similar
to 85% in other reports [1, 6, 8, 15]), with S.
aureus in 38% and CNS in 82% in our study.
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Therefore, our study strengthens the need for
efficient anti-staphylococcal therapy—always
covering CNS—as empirical antibiotic
treatment for infections after surgery for BTs.
Gram-negative bacteria grew in only 26% of BT
patients in our study, mostly in pelvic tumors,
chordomas and early acute infections occurring
\1 month after oncologic surgery compared to
37% in the former literature [11].
The dichotomy in our microbiological
findings was clearer when comparing BTs and
STTs and type of tumor surgery rather than
osteomyelitis and cellulitis, suggesting that
tumor type (BT/STT) and treatment
(prosthesis/non-prosthesis), rather than
postoperative infection time (early, late),
should drive the choice of antibiotic
treatment. Antibiotic therapy duration
C6 weeks was more frequently associated with
successful clinical outcome in BTs (and
osteomyelitis) than a shorter duration
(\6 weeks) of antibiotic therapy (53% vs. 16%;
P = 0.02); therefore, we recommend at least a
6-week duration of antibiotic treatment in BT
patients.
Several limitations of the present study
should be acknowledged. First, it is a
single-center retrospective study of limited size
based on clinical practice. Second, BT and STT
groups differed by several characteristics (such
as sex, age at time of infection and the use of
oncologic preoperative radiotherapy), although
we believe that these factors had little influence
on the bacteriological findings. Third, the
definition of infection used in the present
study might have resulted in the collection of
cases with a wide range of infectious conditions,
resulting in a less homogeneous population.
However, the current study included a relatively
large number of patients, presenting the largest
patient group of postoperatively infected STTs
patients (n = 30) until now, with a
complementary recovery of data from
bacteriological, clinical and histological files.
CONCLUSIONS
Among patients presenting with infection
following malignant tumor resection, the
microbiological spectrum of causative agents is
more often polymicrobial and frequently
involves gram-negative bacteria for STTs,
whereas staphylococci are predominantly
associated with post-BT infections. Thus,
empirical antibiotic treatment of STT
postoperative surgical site infections should
ensure a large coverage of both gram-positive
and -negative bacteria. For infections following
BT surgical resection, empirical antibiotic
treatment should be focused on staphylococci,
supplemented with a coverage of gram-negative
bacteria in the case of early acute infection,
non-prosthetic infections or pelvic BT
localization.
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